Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 2;15(1):23406.
doi: 10.1038/s41598-025-07248-3.

Protein-bound uremic toxin clearance as biomarker of kidney tubular function in diabetic kidney disease

Affiliations

Protein-bound uremic toxin clearance as biomarker of kidney tubular function in diabetic kidney disease

Sabbir Ahmed et al. Sci Rep. .

Abstract

Kidney tubular damage is an important prognostic determinant in diabetic kidney disease (DKD). A vital homeostatic function of the proximal tubule is active tubular secretion of waste products via organic anion transporters (OATs), including protein-bound uremic toxins (PBUTs) that accumulate in plasma in tubular dysfunction. We here hypothesize that PBUT clearance may be a sensitive tubular function marker, and tested this in a DKD mouse model and in type 2 diabetic patients. Among the PBUTs with the highest OAT affinity (i.e., indoxyl sulfate (IS), hippuric acid (HA) and kynurenic acid (KA)), plasma concentrations were higher and urinary excretions were lower 6 and 8 months after DKD induction in mice. These parameters correlated better with tubular atrophy, f4/80 scores and tubular injury markers than conventional filtration markers. In patients, the clearance of IS, HA, KA and p-cresyl sulfate (PCS) was associated with urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1), independent of eGFR. In multiple regression analysis, additionally adjusted for relevant risk factors for tubular injury, the clearance of IS, HA and PCS remained significantly associated with urinary NGAL. In conclusion, IS, HA, KA and PCS clearance may represent a biomarker of kidney tubular function in DKD.

Keywords: Diabetic kidney disease; Hippuric acid; Indoxyl sulfate; Protein-bound uremic toxins; Tubular function marker.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethical approval and consent: The clinical study was registered in the Netherlands Trial Register (NTR 4439), complied with the Declaration of Helsinki and Good Clinical Practice Guidelines, and was approved by the Medical Ethics Committee of the University Medical Center Groningen, the Netherlands (METc 2014/111) (28). All participants (N = 33) provided written informed consent before any study procedure started. All animal experiments were performed with the approval of the Experimental Animal Ethics Committee of the University of Utrecht (DEC number 2009.II.11.129).

Figures

Fig. 1
Fig. 1
PBUTs plasma concentration, surrogate clearance and fractional excretion in DKD mice and healthy controls. Data are presented as mean ± SD. The non-parametric Mann–Whitney U test or parametric unpaired t-test was performed for statistical analysis based on the data normality determined by the Kolmogorov–Smirnov test. ***P < 0.001, **P < 0.01, *P < 0.05. DKD: diabetic kidney disease; IS: indoxyl sulfate; HA: hippuric acid; KA: kynurenic acid.
Fig. 2
Fig. 2
Correlation of f4/80 score with plasma concentration, clearance and fractional excretion of IS (AC), HA (DF), Cr clearance (G), plasma Cr (H), plasma Cys C (I). Non-parametric spearman correlation was performed, and the data are presented as spearman rank, where ‘-’ indicates negative correlation. **P < 0.01, *P < 0.05. IS: indoxyl sulfate; HA: hippuric acid; KA: kynurenic acid; Cr: creatinine; Cys C: cystatin C; uCr: Urinary creatinine.

Similar articles

References

    1. Atkins, R. C. The epidemiology of chronic kidney disease. Kidney Int.67, S14–S18. 10.1111/j.1523-1755.2005.09403.x (2005). - PubMed
    1. Gupta, S., Dominguez, M. & Golestaneh, L. Diabetic Kidney Disease: An Update. Med Clin North Am107, 689–705. 10.1016/j.mcna.2023.03.004 (2023). - PubMed
    1. de Boer, I. H. et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care45, 3075–3090. 10.2337/dci22-0027 (2022). - PMC - PubMed
    1. Rossing, P. et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int.102, 990–999. 10.1016/j.kint.2022.06.013 (2022). - PubMed
    1. Khanijou, V., Zafari, N., Coughlan, M. T., MacIsaac, R. J. & Ekinci, E. I. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease. Diabetes Metab Res Rev38, e3556. 10.1002/dmrr.3556 (2022). - PMC - PubMed

MeSH terms